Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | What makes TGR-1202 different from other PI3K inhibitors?

Owen O'Connor • 9 Jun 2016
EHA 2016
B-Cell Lymphoma Non-Hodgkin Lymphoma TGR-1202 Ublituximab Umbralisib
UNITY-NHL

Owen O’Connor, MD, PhD from Columbia University Medical Center, New York, NY discusses his colleague Dr George Deng’s investigation into the PI3 kinases, with the aim of understanding why TGR-1202 is different from idelalisib and duvelisib. His work has reinforced the knowledge of TGR-1202’s chemical structure and the effect it has on protein translation, specifically Myc protein. Prof. O’Connor also discusses the Phase II UNITY trial (NCT02793583) that aims to assess the efficacy and safety of ublituximab + TGR-1202 and TGR-1202 monotherapy in patients previously treated for diffuse large B-cell lymphoma (DLBCL). Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Owen O'Connor

6:47
Immunoepigenetic platforms for PTCL treatment
Owen O'Connor • 2 Jul 2019
4:42
PTCL arising as a PTLD: the efficacy of pralatrexate
Owen O'Connor • 19 Jun 2019
9:20
The role of epigenetic modulators in the pathogenesis of lymphomas
Anas Younes et al. • 18 Sep 2017
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al. • 8 Sep 2017

Related Videos

3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals